XSHE
301060
Market cap681mUSD
Oct 09, Last price
11.78CNY
1D
2.97%
1Q
36.34%
IPO
-58.67%
Name
Shanghai Labway Clinical Laboratory Co Ltd
Chart & performance
P/E
—
P/S
3.24
EPS
—
Div yield, %
1.75%
Shrs. gr., 5y
1.75%
Rev. gr., 5y
-4.03%
Revenues
1.45b
-16.88%
Net income
-31m
L-71.90%
CFO
269m
+24.29%
Dividend
Jun 08, 20260.18 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shanghai Labway Clinical Laboratory Co., Ltd. provides a dual service offering: comprehensive medical laboratory services and the distribution of in vitro diagnostic (IVD) products. Established in 1993, the company is headquartered in Shanghai, China.
Key people
Weixiong Zeng
Chairman of the Board, General Manager
Zhisen Mao
Deputy General Manager · since 2025
Chuanjiang Wu
Deputy General Manager · since 2025
Jingjing Yang
Secretary of the Board · since 2026
Huijuan Jing
Director · since 2009
Haiyang Wang
Finance Director, Director · since 2024
Huiping Jiang
Independent Director · since 2023
Guohua Qiu
Independent Director · since 2023
Daojin Shi
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||